PELL Bio-Med Technology Co Ltd (6949) Stock Price & Analysis
6949 Stock Chart & Stats
- Day’s Range
- TWD 35.25 - TWD 37.90
- 52-Week Range
- TWD 15.43 - TWD 81.90
- Previous Close
- TWD 38.60
- Volume
- N/A
- Average Volume (3M)
- 3.72M
- Market Cap
- TWD 49.23B
- Enterprise Value
- TWD 55.09B
- Total Cash (Recent Filing)
- TWD 2.27B
- Total Debt (Recent Filing)
- TWD 231.52M
- Price to Earnings (P/E)
- ―
- Beta
- 0.95
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6949 FAQ
What was PELL Bio-Med Technology Co Ltd’s price range in the past 12 months?
What is PELL Bio-Med Technology Co Ltd’s market cap?
When is PELL Bio-Med Technology Co Ltd’s upcoming earnings report date?
How were PELL Bio-Med Technology Co Ltd’s earnings last quarter?
Is PELL Bio-Med Technology Co Ltd overvalued?
Does PELL Bio-Med Technology Co Ltd pay dividends?
What is PELL Bio-Med Technology Co Ltd’s EPS estimate?
How many shares outstanding does PELL Bio-Med Technology Co Ltd have?
What happened to PELL Bio-Med Technology Co Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PELL Bio-Med Technology Co Ltd?
What is the TipRanks Smart Score and how is it calculated?
Company Description
PELL Bio-Med Technology Co Ltd
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Cheng Long Lin
- Employees
- 94
- Website
- www.pellbmt.com
- Address
- No. 87, Xinhu 2nd Rd., Taipei, TP, 114, TW
PELL Bio-Med Technology Co Ltd (6949) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |

